GLP-1 side effects in women: what to expect and what to call about
GLP-1 side effects are common but mostly mild and time-limited. Knowing the typical 8-week trajectory prevents premature discontinuation — and helps distinguish normal from warning.
2 min readReviewed May 2026
Most women starting a GLP-1 will experience side effects in the first 8 weeks. The majority are mild GI symptoms that resolve as the body adapts. A small minority are serious enough to warrant urgent evaluation. Knowing the difference prevents both premature discontinuation and missed warning signs.
The common GI side effects
Nausea is the most common — about 40% of patients on starting doses, declining substantially with titration and time. Typically peaks 1–3 days after each dose increase, then improves. Effective mitigation: take with food or just before a small meal, hydrate well, avoid greasy/heavy meals on dose-bump days, and titrate up more slowly if persistent.
Constipation affects roughly 25% of patients. Driven by slowed gastric emptying plus reduced fiber/water intake (smaller appetite). Mitigation: deliberate fiber and water intake, magnesium citrate at night, brief use of stool softeners if persistent.
Diarrhea affects about 10% — often during dose changes. Usually self-limited. If persistent more than 5–7 days, especially with poor hydration, contact your clinician.
Vomiting is less common (8–10%). If you're vomiting more than once daily or unable to keep fluids down, this requires same-day medical attention.
The hair shedding question
About 15% of GLP-1 users notice increased hair shedding around 3–6 months after starting. The driver is rapid weight loss (telogen effluvium), not the medication itself — same phenomenon happens with surgical weight loss. Hair typically recovers 6–9 months after weight loss stabilizes. Adequate protein and iron intake during weight loss reduces shedding.
The muscle loss issue
Body composition studies of GLP-1 weight loss show roughly 25–35% of weight lost is lean tissue (muscle plus organ mass). For women approaching menopause — when bone density and muscle mass are already at risk — this matters more than it does for younger populations. Mitigation: protein at every meal (target 1.6–2.0 g/kg ideal body weight daily during active weight loss), resistance training 2–3x weekly, and tracking grip strength or functional fitness as you lose weight.
Serious but uncommon side effects
Pancreatitis: severe upper abdominal pain radiating to the back, often with nausea and vomiting. Incidence is uncommon but elevated vs general population. Stop the medication and seek same-day evaluation. History of pancreatitis is a relative contraindication to GLP-1.
Gallstones: rapid weight loss of any kind increases gallstone risk, including with GLP-1. Symptoms: right upper quadrant pain, particularly after meals, sometimes with nausea. Evaluation as outpatient unless severe.
Diabetic retinopathy worsening: in patients with pre-existing diabetic retinopathy, rapid glycemic control can transiently worsen retinopathy. Ophthalmology follow-up if you have diabetes and pre-existing eye changes.
Thyroid medullary carcinoma signal: in rodent studies, GLP-1 agonists increased risk of medullary thyroid C-cell tumors. Human evidence is unclear. Contraindicated if personal or family history of MEN-2 syndrome or medullary thyroid cancer.
When to call your clinician
Same-day: severe abdominal pain, persistent vomiting unable to keep fluids down, signs of dehydration. Within a week: persistent diarrhea beyond 5–7 days, severe constipation unresponsive to mitigation, abnormal mood changes, suicidal ideation (rare but reported). Routine visit: persistent mild nausea beyond 8 weeks, plateau in weight loss, questions about dose adjustment.
Informational only — adverse symptoms require clinical evaluation by your prescriber.